Legacies: 60 biopharma pioneers over 60 who helped birth a tech revolution in the making

There’s a whole generation of living pioneers who have been breaking new paths in R&D for decades. Endpoints News shares their list of standouts who have earned recognition for a lifetime’s devotion to the field.

We’re excited to share our Vertex Ventures HC's Venture Advisor, George Golumbeski, has been recognized for his legacy in Biopharma in this Endpoints' 60 over 60 list. Here’s an except from John Carroll, Editor and Founder of Endpoints News:

George Golumbeski

Almost exactly 3 years ago George Golumbeski quietly slipped out the back door at Celgene after leading an epic charge on the BD front for the most optimistic bull biotech in the industry. Under CEO Bob Hugin, Golumbeski — partnered with Tom Daniel — was charged with building an entire pipeline. And he did it in style — specializing in their you-stay-in-charge approach with partners that supplied money and help without a lot of the soul-crushing dictates that can come from a giant partner in drug development. “I’m in a good place,” he told me about his departure, with plans to lend a hand at the next generation of up-and-coming biotechs. “I want to help to the extent I can with these young companies.”

Celgene had its own problems after a management handoff, but Golumbeski nevertheless helped deliver a string of new drugs that Bristol Myers is now championing. As for the BD wiz, he’s gone on to a host of insider positions, mentoring companies around the world as chair or board member. Golumbeski remains the best connected player in biotech, an industry where connections are crucial.

Read the full article on Endpoints News here.